Bladder cancer trial using light therapy in the bladder
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests a treatment called photodynamic therapy (PDT) placed directly into the bladder. It may help people whose non–muscle-invasive bladder cancer did not respond to BCG treatment or could not tolerate it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and willing to sign consent for the study.
- Your bladder cancer diagnosis is confirmed by biopsy as high-grade CIS (with or without resected early tumors), and your latest bladder scope/biopsy was within 12 weeks.
- You have BCG intolerance or BCG-unresponsive disease based on your past BCG dose history.
- You cannot safely have bladder removal surgery (cystectomy) or you choose not to have it.
- Your bladder can hold the study medicine for at least 60 minutes, and you can attend all study visits for about 15 months.
- If you can become pregnant, you must have a negative pregnancy test and use two birth-control methods (or be surgically sterile, or avoid heterosexual pregnancy for a set time).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
This trial tests whether radiation therapy can help people whose bladder cancer (specifically carcinoma in situ) did not get better with BCG treatment and who are not having their bladder removed. It aims to offer a less invasive option for controlling the cancer.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
Hear when a new Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.